Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 4:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "resistant hypertension" Condition: Hypertension Clear all
Recruiting No phase listed Observational

Real World Observational Study of Sotatercept for Pulmonary Hypertension

NCT06751082
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Jul 24, 2026, 4:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of the Relationship Between Blood Vessels and Insulin Response in Adolescents

NCT00374361
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Hypertension, Heart Disease, Stroke
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
8 Years to 18 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Jul 24, 2026, 4:58 PM EDT
Terminated Phase 2 Interventional Results available

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

NCT02927366
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
QCC374, Placebo Matching
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Jul 24, 2026, 4:58 PM EDT
Active, not recruiting Not applicable Interventional

Electronic Alert to Improve Testing For Primary Aldosteronism in Patients With Hypertension

NCT05925569
View directory record Official record
Conditions
Primary Aldosteronism, Resistant Hypertension, Secondary Hypertension, Hyperaldosteronism, Mineralocorticoid Excess, Hypertension
Interventions
Best Practice Advisory Computerized Alert
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
12,501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 6, 2025 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Results available

Effect of Sitagliptin and an ACE Inhibitor on Blood Pressure in Metabolic Syndrome

NCT00666848
View directory record Official record
Conditions
Metabolic Syndrome, Hypertension
Interventions
Placebo, Enalapril 5mg, Enalapril 10mg, Sitagliptin
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2012 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

A Mobile Health Intervention in Pulmonary Arterial Hypertension

NCT03069716
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Idiopathic Pulmonary Arterial Hypertension, Heritable Pulmonary Arterial Hypertension, Associated Pulmonary Arterial Hypertension
Interventions
Smartphone Text Messaging, Fitbit Charge HR
Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Jul 24, 2026, 4:58 PM EDT
Active, not recruiting Phase 2 Interventional

Allopurinol Improves Heart Function in African Americans With Resistant Hypertension

NCT05888233
View directory record Official record
Conditions
Heart Failure Preserved Ejection Fraction, Resistant Hypertension
Interventions
Allopurinol
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

Preventing Metabolic Side Effects of Thiazide Diuretics With KMgCitrate

NCT02665117
View directory record Official record
Conditions
Hypertension
Interventions
Potassium Magnesium Citrate (KMgCit), Potassium Chloride (KCl), Chlorthalidone
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
21 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
3
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 24, 2023 · Synced Jul 24, 2026, 4:58 PM EDT
Not listed Not applicable Interventional

TReatment Of Pulmonary HYpertension 1-US Study

NCT02835950
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Therapeutic Intra-Vascular UltraSound (TIVUS™) System
Device
Lead sponsor
SoniVie Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
4
States / cities
San Diego, California • Ann Arbor, Michigan • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional

Evaluating Weight Loss Programs for Obese People at Risk for Heart Disease (The POWER Study)

NCT00783315
View directory record Official record
Conditions
Obesity
Interventions
Call-Center Directed (CCD) Weight Loss Program, In-Person Directed (IPD) Weight Loss Program, Self-Directed Weight Loss Program
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years and older
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 4, 2018 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional Results available

Effects of the Dietary Approaches to Stop Hypertension(DASH) Sodium-restricted Diet in Diastolic Heart Failure

NCT00939640
View directory record Official record
Conditions
Diastolic Heart Failure, Hypertensive Heart Disease
Interventions
DASH/sodium-restricted diet (SRD)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
50 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 14, 2019 · Synced Jul 24, 2026, 4:58 PM EDT
Completed No phase listed Observational

International BPA Registry

NCT03245268
View directory record Official record
Conditions
Chronic Thromboembolic Pulmonary Hypertension, CTEPH
Interventions
Balloon pulmonary angioplasty
Procedure
Lead sponsor
International CTEPH Association
Other
Eligibility
Not listed
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
5
States / cities
La Jolla, California • Boston, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Jul 24, 2026, 4:58 PM EDT
Terminated Phase 3 Interventional

DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protocol DAR-311) of Darusentan in Resistant Hypertension

NCT00353574
View directory record Official record
Conditions
Hypertension
Interventions
Darusentan
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
35 Years to 80 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
53
States / cities
Mobile, Alabama • Tucson, Arizona • Inglewood, California + 48 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Omega-3 Fatty Acids on Markers of Inflammation

NCT01129050
View directory record Official record
Conditions
Obesity, Hypertriglyceridemia, Insulin Resistance, Hypertension
Interventions
Fish Oil, Flaxseed Oil, Placebo
Dietary Supplement
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Phase 4 Interventional Results available

Acute Hemodynamic Effects of Sildenafil in Patients With Severe Aortic Stenosis

NCT01060020
View directory record Official record
Conditions
Aortic Stenosis
Interventions
Sildenafil
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 24, 2018 · Synced Jul 24, 2026, 4:58 PM EDT
Recruiting Phase 4 Interventional

Dopamine vs. Norepinephrine for Hypotension in Neonates With Pulmonary Hypertension (DONE)

NCT07322133
View directory record Official record
Conditions
Hypotension and Shock, Pulmonary Hypertension of the Newborn (PPHN), Hypoxemic Respiratory Failure
Interventions
Dopamine administration, Norepinephrine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
Up to 28 Days
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Jul 24, 2026, 4:58 PM EDT
Terminated Not applicable Interventional Results available

Effects of TNF-alpha Antagonism (Etanercept) in Patients With the Metabolic Syndrome and Psoriasis

NCT00477191
View directory record Official record
Conditions
Psoriasis, Metabolic Syndrome, Hyperlipidemia, Obesity, Hypertension
Interventions
Etanercept
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Phase 2 Interventional Results available

The SCCS Polypill Pilot Trial

NCT02278471
View directory record Official record
Conditions
Hypertension, Hyperlipidemia
Interventions
Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
45 Years to 75 Years
Enrollment
303 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Jul 24, 2026, 4:58 PM EDT
Recruiting Phase 2 Interventional

Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis

NCT03630211
View directory record Official record
Conditions
Systemic Sclerosis, Diffuse Sclerosis Systemic, Interstitial Lung Disease, Pulmonary Hypertension
Interventions
Cyclophosphamide, Mesna, Rituximab, Alemtuzumab, Thiotepa, GM-CSF, Intravenous immunoglobulin, Total Body Irradiation, Anti Thymocyte Globulin
Drug · Radiation
Lead sponsor
Paul Szabolcs
Other
Eligibility
8 Years to 60 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Jul 24, 2026, 4:58 PM EDT
Withdrawn Phase 3 Interventional

Secondary Prophylaxis of Gastrointestinal Bleeding in Cirrhotic Patients Using THALIDOMIDE

NCT00787436
View directory record Official record
Conditions
Gastrointestinal Hemorrhage, Portal Hypertension
Interventions
Thalidomide
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2013 · Synced Jul 24, 2026, 4:58 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Treatment of Insulin Resistance in Hypertensive, Obese Adolescents

NCT00185705
View directory record Official record
Conditions
Hypertension, Insulin Resistance, Dyslipidemia
Interventions
Telmisartan
Drug
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Not applicable Interventional

A Pilot Study of a Lifestyle Intervention on the Metabolic Syndrome (3ELM Study)

NCT02233088
View directory record Official record
Conditions
Metabolic Syndrome
Interventions
ELM Group, ELM Classes, ELM Individual
Behavioral · Other
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 72 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 11, 2023 · Synced Jul 24, 2026, 4:58 PM EDT
Active, not recruiting Not applicable Interventional

The RADIANCE II Pivotal Study: A Study of the ReCor Medical Paradise System in Stage II Hypertension

NCT03614260
View directory record Official record
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions
Paradise Renal Denervation System, Renal Angiogram
Device · Procedure
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • Bridgeport, Connecticut + 24 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Jul 24, 2026, 4:58 PM EDT
Completed Phase 3 Interventional

Firibastat in Treatment-resistant Hypertension

NCT04277884
View directory record Official record
Conditions
Hypertension
Interventions
Firibastat, Placebo
Drug
Lead sponsor
Quantum Genomics SA
Industry
Eligibility
18 Years and older
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
15
States / cities
Birmingham, Alabama • Huntington Beach, California • Tustin, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Jul 24, 2026, 4:58 PM EDT